Gentamicin ( DrugBank: Gentamicin )
3 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
36 | 表皮水疱症 | 7 |
113 | 筋ジストロフィー | 2 |
299 | 嚢胞性線維症 | 1 |
36. 表皮水疱症
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04644627 (ClinicalTrials.gov) | December 1, 2020 | 20/11/2020 | Topical Gentamicin Nonsense Suppression Therapy of EB | TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS | Epidermolysis Bullosa | Drug: Gentamicin Sulfate | Oslo University Hospital | NULL | Completed | N/A | N/A | All | 4 | Phase 1/Phase 2 | Norway |
2 | EUCTR2020-002337-15-NO (EUCTR) | 16/09/2020 | 29/06/2020 | TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA | TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY) - GENTELBULL | Epidermolysis bullosa caused by nonsense mutations or splice site mutations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Infectogenta Product Name: Gentamicin sulfate 0.1% ointment | Oslo University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | Norway | ||
3 | NCT04140786 (ClinicalTrials.gov) | October 31, 2019 | 23/10/2019 | Optimizing IV Gentamicin in JEB | Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations | Junctional Epidermolysis Bullosa | Drug: Gentamicin Sulfate, Injectable | University of Southern California | NULL | Recruiting | 30 Days | N/A | All | 6 | Phase 1/Phase 2 | United States |
4 | NCT03392909 (ClinicalTrials.gov) | July 5, 2018 | 2/1/2018 | Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment | Recessive Dystrophic Epidermolysis Bullosa | Drug: Gentamicin | University of Southern California | NULL | Recruiting | 7 Years | N/A | All | 9 | Phase 1/Phase 2 | United States |
5 | NCT03526159 (ClinicalTrials.gov) | June 1, 2018 | 17/4/2018 | Gentamicin for Junctional Epidermolysis Bullosa | A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment | Junctional Epidermolysis Bullosa | Drug: Gentamicin Sulfate | University of Southern California | NULL | Recruiting | N/A | N/A | All | 6 | Phase 1/Phase 2 | United States |
6 | NCT03012191 (ClinicalTrials.gov) | February 2, 2017 | 4/1/2017 | Gentamicin for RDEB | Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations | Recessive Dystrophic Epidermolysis Bullosa | Drug: Gentamicin Sulfate | University of Southern California | NULL | Completed | N/A | N/A | All | 6 | Phase 1/Phase 2 | United States |
7 | NCT02698735 (ClinicalTrials.gov) | February 25, 2016 | 19/2/2016 | Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients | Recessive Dystrophic Epidermolysis Bullosa | Drug: Gentamicin;Drug: Placebo | University of Southern California | NULL | Completed | N/A | N/A | All | 5 | Phase 1/Phase 2 | NULL |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00451074 (ClinicalTrials.gov) | March 2007 | 21/3/2007 | Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons | A Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations | Duchenne Muscular Dystrophy | Drug: Gentamicin infusions twice a week for six months | Nationwide Children's Hospital | National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 5 Years | 20 Years | Male | 12 | Phase 1 | United States |
2 | NCT00005574 (ClinicalTrials.gov) | February 2000 | 2/5/2000 | Gentamicin Treatment of Muscular Dystrophy | Gentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in Dystrophin | Becker Muscular Dystrophy;Duchenne Muscular Dystrophy | Drug: Gentamicin | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 4 | Phase 1 | United States |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00376428 (ClinicalTrials.gov) | January 2003 | 13/9/2006 | Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients | Application of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Gentamicin | Assistance Publique - Hôpitaux de Paris | NULL | Terminated | N/A | N/A | Both | 20 | Phase 2 | France |